Sclerosis
Welcome,         Profile    Billing    Logout  
 125 Companies   183 Products   183 Products   133 Mechanisms of Action   1 Trial   2306 News 


12345678910111213...4041»
  • ||||||||||  Trial completion, Enrollment change:  Lipoic Acid as a Treatment for Acute Optic Neuritis (clinicaltrials.gov) -  Apr 26, 2019   
    P1,  N=31, Completed, 
    N=86 --> 40 | Recruiting --> Terminated; interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab Recruiting --> Completed | N=54 --> 31
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Phase classification:  CogMS: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients (clinicaltrials.gov) -  Mar 6, 2019   
    P=N/A,  N=63, Completed, 
    Recruiting --> Completed | Trial completion date: Dec 2014 --> Dec 2018 Phase classification: P4 --> P=N/A
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Mindfulness-based Stress Reduction in Multiple Sclerosis (clinicaltrials.gov) -  Mar 1, 2019   
    P=N/A,  N=50, Completed, 
    Phase classification: P4 --> P=N/A Recruiting --> Completed | Trial completion date: Aug 2015 --> Aug 2016 | Trial primary completion date: Aug 2015 --> Aug 2016
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  SAMSPAP: Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial (clinicaltrials.gov) -  Jan 12, 2019   
    P=N/A,  N=49, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018
  • ||||||||||  Campath (alemtuzumab) / Sanofi
    Trial completion date, Trial withdrawal, Trial primary completion date:  Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis (clinicaltrials.gov) -  Jan 8, 2019   
    P1/2,  N=0, Withdrawn, 
    Recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018 Trial completion date: Jan 2020 --> Sep 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2020 --> Aug 2018
  • ||||||||||  Betaseron (IFN-β-1b) / Bayer
    Phase classification:  Betaseron Pregnancy Registry (clinicaltrials.gov) -  Dec 12, 2018   
    P=N/A,  N=113, Completed, 
    Trial completion date: Jan 2020 --> Sep 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2020 --> Aug 2018 Phase classification: P4 --> P=N/A
  • ||||||||||  Enrollment change, Trial withdrawal:  Stem Cell Therapy for Amyotrophic Lateral Sclerosis (clinicaltrials.gov) -  Oct 25, 2018   
    P2,  N=0, Withdrawn, 
    Active, not recruiting --> Completed | N=100 --> 135 | Trial completion date: Feb 2018 --> Oct 2018 N=57 --> 0 | Completed --> Withdrawn
  • ||||||||||  autologous mesenchymal stem cells / Tianjin Medical University General Hospital
    Trial completion, Phase classification:  Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) -  Oct 17, 2018   
    P2a,  N=15, Completed, 
    Enrolling by invitation --> Completed | N=1920 --> 1276 Recruiting --> Completed | Phase classification: P2 --> P2a
  • ||||||||||  Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) -  Sep 10, 2018   
    P=N/A,  N=0, Withdrawn, 
    Recruiting --> Completed | Trial completion date: Mar 2018 --> Jan 2017 | Trial primary completion date: Mar 2018 --> Dec 2016 N=15 --> 0 | Trial completion date: Jun 2018 --> Sep 2018 | Suspended --> Withdrawn | Trial primary completion date: Jun 2018 --> Sep 2018
  • ||||||||||  Trial completion, Enrollment change:  Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life (clinicaltrials.gov) -  Sep 5, 2018   
    P=N/A,  N=431, Completed, 
    N=15 --> 0 | Trial completion date: Jun 2018 --> Sep 2018 | Suspended --> Withdrawn | Trial primary completion date: Jun 2018 --> Sep 2018 Recruiting --> Completed | N=264 --> 431
  • ||||||||||  Trial completion, Phase classification, Trial completion date, Trial primary completion date:  SIAMMS-II: Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (clinicaltrials.gov) -  Aug 23, 2018   
    P=N/A,  N=4, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Phase classification: P1 --> PN/A | Trial completion date: Sep 2016 --> Aug 2018 | Trial primary completion date: Sep 2016 --> Sep 2017
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date, HEOR:  ermoSla: Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) -  Aug 7, 2018   
    P=N/A,  N=65, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Apr 2018 | Trial primary completion date: Jul 2016 --> Dec 2017
  • ||||||||||  Trial completion:  A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) -  Jul 26, 2018   
    P=N/A,  N=282, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Apr 2018 | Trial primary completion date: Jul 2016 --> Dec 2017 Active, not recruiting --> Completed
  • ||||||||||  Trial completion:  Power Over Pain (POP) Study (clinicaltrials.gov) -  Jun 27, 2018   
    P=N/A,  N=177, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Biomarker, Enrollment change, Trial termination:  Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis (clinicaltrials.gov) -  Jun 6, 2018   
    P=N/A,  N=6, Terminated, 
    Active, not recruiting --> Completed N=17 --> 6 | Active, not recruiting --> Terminated; Principal investigator was unable to fulfill his responsibilities.
  • ||||||||||  Trial termination:  Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS) (clinicaltrials.gov) -  Jun 4, 2018   
    P=N/A,  N=20, Terminated, 
    N=17 --> 6 | Active, not recruiting --> Terminated; Principal investigator was unable to fulfill his responsibilities. Recruiting --> Terminated; Principle Investigator was unable to fulfill responsibilities.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Implementing Physical Activity Guidelines for Adults With MS (clinicaltrials.gov) -  Jun 1, 2018   
    P=N/A,  N=94, Completed, 
    Trial completion date: Oct 2019 --> Oct 2018 Recruiting --> Completed | Trial completion date: Mar 2017 --> Mar 2018 | Trial primary completion date: Dec 2016 --> Mar 2018
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) -  May 30, 2018   
    P1,  N=2, Terminated, 
    Recruiting --> Completed | Trial completion date: Mar 2017 --> Mar 2018 | Trial primary completion date: Dec 2016 --> Mar 2018 N=100 --> 2 | Trial completion date: Jan 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> May 2018
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Trial completion:  Ireland Natalizumab (TYSABRI) Observational Program (clinicaltrials.gov) -  May 4, 2018   
    P=N/A,  N=191, Completed, 
    N=100 --> 2 | Trial completion date: Jan 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> May 2018 Active, not recruiting --> Completed